131 related articles for article (PubMed ID: 37788955)
1. Performance of nonalcoholic fatty liver fibrosis score in estimating atherosclerotic cardiovascular disease risk.
Huang YC; Huang JC; Chien HH; Lin CI; Chuang YS; Cheng HY; Lin WT; Lin YY; Chuang HY; Ho CK; Wang CL; Dai CY
Nutr Metab Cardiovasc Dis; 2023 Dec; 33(12):2479-2487. PubMed ID: 37788955
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease.
Kim Y; Han E; Lee JS; Lee HW; Kim BK; Kim MK; Kim HS; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Lee YH; Kim SU
Gut Liver; 2022 Mar; 16(2):290-299. PubMed ID: 34238770
[TBL] [Abstract][Full Text] [Related]
3. Histological severity of nonalcoholic fatty liver disease is associated with 10-year risk for atherosclerotic cardiovascular disease.
Park JH; Koo BK; Kim W; Kim WH;
Hepatol Int; 2021 Oct; 15(5):1148-1159. PubMed ID: 34081289
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic Fatty Liver Disease and Sarcopenia Are Independently Associated With Cardiovascular Risk.
Han E; Lee YH; Kim YD; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Han KH; Nam HS; Heo JH; Kim SU
Am J Gastroenterol; 2020 Apr; 115(4):584-595. PubMed ID: 32141917
[TBL] [Abstract][Full Text] [Related]
5. Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease.
Han E; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Kim SU
Gut Liver; 2022 Sep; 16(5):786-797. PubMed ID: 35321955
[TBL] [Abstract][Full Text] [Related]
6. Association of Physical Activity With Risk of Liver Fibrosis, Sarcopenia, and Cardiovascular Disease in Nonalcoholic Fatty Liver Disease.
Chun HS; Lee M; Lee HA; Oh SY; Baek HJ; Moon JW; Kim YJ; Lee J; Kim H; Kim HY; Yoo K; Kim TH; Kim SU
Clin Gastroenterol Hepatol; 2023 Feb; 21(2):358-369.e12. PubMed ID: 34998993
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease.
Nadinskaia M; Maevskaya M; Ivashkin V; Kodzoeva K; Pirogova I; Chesnokov E; Nersesov A; Kaibullayeva J; Konysbekova A; Raissova A; Khamrabaeva F; Zueva E
World J Gastroenterol; 2021 Mar; 27(10):959-975. PubMed ID: 33776366
[TBL] [Abstract][Full Text] [Related]
8. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Cardiovascular Risk in Patient with Primary Non-alcoholic Fatty Liver Disease.
Pisetta C; Chillè C; Pelizzari G; Pigozzi MG; Salvetti M; Paini A; Muiesan ML; De Ciuceis C; Ricci C; Rizzoni D
High Blood Press Cardiovasc Prev; 2020 Aug; 27(4):321-330. PubMed ID: 32436128
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Fatty Liver Disease as an Emerging Risk Factor and Potential Intervention Target for Atherosclerotic Cardiovascular Diseases.
Zhang D; Mi Z; Peng J; Yang T; Han Y; Zhai Y; Song C; Teng X; Sun W; Guo J; Bilonda KP
J Cardiovasc Pharmacol; 2023 May; 81(5):327-335. PubMed ID: 36917556
[TBL] [Abstract][Full Text] [Related]
11. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: A nationwide study.
Han E; Chun HS; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Lee BW; Kang ES; Cha BS; Ahn SH; Kim SU
J Gastroenterol Hepatol; 2023 Sep; 38(9):1598-1609. PubMed ID: 37321651
[TBL] [Abstract][Full Text] [Related]
12. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.
Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI
Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799
[TBL] [Abstract][Full Text] [Related]
13. Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population.
Pennisi G; Di Marco V; Buscemi C; Mazzola G; Randazzo C; Spatola F; Craxì A; Buscemi S; Petta S
J Gastroenterol Hepatol; 2021 Sep; 36(9):2389-2396. PubMed ID: 33871081
[TBL] [Abstract][Full Text] [Related]
14. "Dangerous liaisons: NAFLD and liver fibrosis increase cardiovascular risk in HIV".
Cervo A; Sebastiani G; Milic J; Krahn T; Mazzola S; Petta S; Cascio A; Guaraldi G; Mazzola G
HIV Med; 2022 Sep; 23(8):911-921. PubMed ID: 35199429
[TBL] [Abstract][Full Text] [Related]
15. Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study.
Lee SB; Park GM; Lee JY; Lee BU; Park JH; Kim BG; Jung SW; Jeong ID; Bang SJ; Shin JW; Park NH; Yang DH; Kang JW; Lim TH; Kim HK; Choe J; Lee HC
J Hepatol; 2018 May; 68(5):1018-1024. PubMed ID: 29274406
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Innovative and Traditional Cardiometabolic Indices in Estimating Atherosclerotic Cardiovascular Disease Risk in Adults.
Huang YC; Huang JC; Lin CI; Chien HH; Lin YY; Wang CL; Liang FW; Dai CY; Chuang HY
Diagnostics (Basel); 2021 Mar; 11(4):. PubMed ID: 33800660
[TBL] [Abstract][Full Text] [Related]
17. Early-stage non-alcoholic fatty liver disease in relation to atherosclerosis and inflammation.
Tan SH; Zhou XL
Clinics (Sao Paulo); 2023; 78():100301. PubMed ID: 37952443
[TBL] [Abstract][Full Text] [Related]
18. Comparison of anthropometric measurements for prediction of the atherosclerosis and liver histology in young adults with nonalcoholic fatty liver disease.
Dogan T; Ozturk K; Celikkanat S; Aykan MB; Uygun A
Eur J Gastroenterol Hepatol; 2019 Nov; 31(11):1460-1466. PubMed ID: 31045630
[TBL] [Abstract][Full Text] [Related]
19. Association of fat-to-muscle ratio with non-alcoholic fatty liver disease: a single-centre retrospective study.
Yan F; Nie G; Zhou N; Zhang M; Peng W
BMJ Open; 2023 Oct; 13(10):e072489. PubMed ID: 37903611
[TBL] [Abstract][Full Text] [Related]
20. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease.
Xu HW; Hsu YC; Chang CH; Wei KL; Lin CL
Hepatol Int; 2016 Mar; 10(2):340-6. PubMed ID: 26676626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
